

# Fiscal Year 2010 Annual Review of Nasal Allergy Products

Oklahoma Health Care Authority, April 2011

## Current Prior Authorization of Nasal Allergy Products

1. The following criteria are required for approval of a Tier 2 product (or a Tier 3 product if no Tier 2 exists):
  - a. Documented adverse effect or contraindication to the preferred products.
  - b. Failure with Tier 1 medications defined as no beneficial response after at least three weeks use of each during which time the drug has been titrated to the recommended dose. All available Tier 1 corticosteroids should be tried prior to approval of higher Tiered products).
2. The following criteria are required for approval of a Tier 3 product:
  - a. All Tier 2 criteria must be met.
  - b. Failure with all available Tier 2 products defined as no beneficial response after at least three weeks use of each during which time the drug has been titrated to the recommended dose.
3. Approvals will be for the duration of three months, except for members with chronic diseases such as asthma or COPD, in which case authorizations will be for the duration of one year.

All products also have quantity limits in place, based on the FDA approved maximum dose.

Nasal Allergy Products		
Tier 1	Tier 2	Tier 3
<b>Corticosteroids</b>		
fluticasone (Flonase®) flunisolide (Nasalide®, Nasarel™)	Beclomethasone (Beconase® AQ ) Triamcinolone (Nasacort® AQ) Olapatadine (Patanase®) Mometasone (Nasonex®)	Ciclesonide (Omnaris™) Budesonide (Rhinocort® AQ) Fluticasone (Veramyst™)
<b>Other</b>		
Ipratropium		Azelastine (Astepro®) Azelastrine (Astelin®)


\*Mandatory Generic Plan Applies.

Blue color indicates supplemental rebate program participation.

## Trends in Utilization

Fiscal Year	Members	Claims	Cost	Cost/ Claim	Per-Diem	Units	Days
2009	36,308	68,496	\$4,113,718.29	\$60.06	\$1.85	1,060,740	2,226,233
2010	41,269	74,169	\$3,138,488.62	\$42.32	\$1.27	1,137,420	2,473,415
% Change	13.7%	8.3%	-23.7%	-29.5%	-31.4%	7.2%	11.1%
Change	4,961	5,673	-\$975,229.67	-\$17.74	-\$0.58	76,680	247,182


## Member Demographics for Fiscal Year 2010



## Top 10 Prescribers of Nasal Allergy Products: FY 2010

Specialty	Total Claims	Total Cost	Comparison By Number of Claims
Family Practitioner	18,870	\$713,641.47	18,870
General Pediatrician	17,120	\$823,986.62	17,120
Nurse Practitioner (Other)	10,642	\$514,486.96	10,642
Physician Assistant	7,168	\$293,803.75	7,168
Non-OHCA Contracted Prescriber	4,446	\$128,605.29	4,446
General Practitioner	3,039	\$94,327.95	3,039
Otologist, Laryngologist, Rhinologist	2,668	\$131,761.22	2,668
Internist	2,093	\$65,252.84	2,093
DDSD-NFM	1,529	\$72,867.32	1,529
Allergist	1,360	\$70,867.32	1,360

## Prior Authorization of Nasal Allergy Products: FY 2010



## Market Changes

- The patent for Nasacort AQ® will expire in 2016, however an agreement between Sanofi and a generic manufacturer may mean a generic will be available in 2011. However, this generic is not expected to generate significant savings for the state.
- The patent for Patanase® will be expiring in the next two years and a generic may be available as early as December 2012.
- A generic is now available for Astelin®, however the generic company has an infringement agreement in place until February 2011. This product may be considered for placement in Tier 1 once additional generics are available on the market.

## Recommendations

The College of Pharmacy does not recommend any changes to the current Product Based Prior Authorization program for Nasal Allergies at this time.

## Product Utilization Details

Product	Claims	Units	Days	Members	Total Paid	Claims / Member	Paid/ Day	% Cost
<b>Corticosteroids</b>								
Fluticasone	47,815	764,611	1,600,354	29,734	\$797,418.45	1.61	\$0.50	25.41%
Flonase®	18	288	656	15	\$1,505.29	1.2	\$2.29	0.05%
Flunisolide 0.025%	1,115	27,964	37,170	785	\$26,463.38	1.42	\$0.71	0.84%
Flunisolide 29 mcg	722	18,200	22,161	532	\$15,638.06	1.36	\$0.71	0.50%
Veramyst®	16,123	161,138	533,287	9,943	\$1,519,531.57	1.62	\$2.85	48.42%
Nasacort AQ®	5,900	98,760	200,498	3,299	\$588,889.98	1.79	\$2.94	18.76%
Patanase®	510	15,555	16,759	362	\$49,097.67	1.41	\$2.93	1.56%
Nasonex®	199	3,383	6,419	149	\$18,746.50	1.34	\$2.92	0.60%
Beconase AQ®	137	3,475	4,257	73	\$18,963.17	1.88	\$4.45	0.60%
Rhinocort AQ®	48	413	1,590	41	\$4,437.47	1.17	\$2.79	0.14%
Omnaris®	17	213	570	6	\$1,275.08	2.83	\$2.24	0.04%
<b>Others</b>								
Astepro® 137 mcg	449	13,470	14,398	325	\$42,096.76	1.38	\$2.92	1.34%
Astepro® 0.15%	24	720	800	13	\$2,093.90	1.85	\$2.62	0.07%
Astelin®	446	13,367	14,113	270	\$43,271.17	1.65	\$3.07	1.38%
Ipratropium 0.03%	436	12,624	13,945	325	\$6,814.14	1.34	\$0.49	0.22%
Ipratropium 0.06%	210	3,240	6,438	139	\$2,246.03	1.51	\$0.35	0.07%
<b>Totals</b>	<b>74,169</b>	<b>1,137,421</b>	<b>2,473,415</b>	<b>41,269*</b>	<b>\$3,138,488.62</b>	<b>1.8</b>	<b>\$1.27</b>	

\*Unduplicated members.